Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
Fiche publication
Date publication
février 2024
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
Tous les auteurs :
Scherer L, Soudant M, Pittion-Vouyovitch S, Debouverie M, Guillemin F, Epstein J, Mathey G
Lien Pubmed
Résumé
one of the most important therapeutic goals in relapse-onset multiple sclerosis is to preclude conversion to secondary progression. Our objective was to determine the risk of progression associated with natalizumab treatment in an registry-based cohort of patients and to identify determinant factors.
Mots clés
Multiple sclerosis, Natalizumab, Observational study, Secondary progression
Référence
J Neurol. 2024 02 29;: